Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jamie K Capal

Showing results (21-30 of 34) with videos related to

Pageof 4
Sort By:
Pediatric Neurology|August 29, 2017
Utility of the Autism Observation Scale for Infants in Early Identification of Autism in Tuberous Sclerosis ComplexJamie K Capal, Paul S Horn, Donna S Murray, et al.
The American Psychologist|April 5, 2019
Impacting development in infants with tuberous sclerosis complex: Multidisciplinary research collaborationMarian E Williams, Deborah A Pearson, Jamie K Capal, et al.
Nature Reviews. Drug Discovery|May 18, 2021
Clinical trial strategies for rare neurodevelopmental disorders: challenges and opportunitiesMichelle L Krishnan, Elizabeth Berry-Kravis, Jamie K Capal, et al.
European Journal of Paediatric Neurology : EJPN : Official Journal of the European Paediatric Neurology Society|July 15, 2018
Short-term safety of mTOR inhibitors in infants and very young children with tuberous sclerosis complex (TSC): Multicentre clinical experienceDarcy A Krueger, Jamie K Capal, Paolo Curatolo, et al.
BMC Medicine|August 8, 2023
Understanding the impact of tuberous sclerosis complex: development and validation of the TSC-PROMAnnelieke R Müller, Michiel A J Luijten, Lotte Haverman, et al.
BMC Medicine|October 23, 2023
Correction: Understanding the impact of tuberous sclerosis complex: development and validation of the TSC-PROMAnnelieke R Müller, Michiel A J Luijten, Lotte Haverman, et al.
Annals of the Child Neurology Society|December 27, 2024
Preventative treatment of tuberous sclerosis complex with sirolimus: Phase I safety and efficacy resultsJamie K Capal, David M Ritter, David Neal Franz, et al.
Molecular Cancer Research : MCR|July 16, 2017
Tuberin Regulates Prostaglandin Receptor-Mediated Viability, via Rheb, in mTORC1-Hyperactive CellsChenggang Li, Xiaolei Liu, Yang Liu, et al.
Frontiers in Psychiatry|March 17, 2022
Empowering Families Through Technology: A Mobile-Health Project to Reduce the TAND Identification and Treatment Gap (TANDem)Tosca-Marie Heunis, Stacey Bissell, Anna W Byars, et al.
Journal of Neurodevelopmental Disorders|September 14, 2023
International consensus recommendations for the identification and treatment of tuberous sclerosis complex-associated neuropsychiatric disorders (TAND)Petrus J de Vries, Tosca-Marie Heunis, Stephanie Vanclooster, et al.
Pageof 4

Showing results (21-30 of 34) with videos related to

Sort By:
Pageof 4
Pediatric Neurology|August 29, 2017
Utility of the Autism Observation Scale for Infants in Early Identification of Autism in Tuberous Sclerosis ComplexJamie K Capal, Paul S Horn, Donna S Murray, et al.
The American Psychologist|April 5, 2019
Impacting development in infants with tuberous sclerosis complex: Multidisciplinary research collaborationMarian E Williams, Deborah A Pearson, Jamie K Capal, et al.
Nature Reviews. Drug Discovery|May 18, 2021
Clinical trial strategies for rare neurodevelopmental disorders: challenges and opportunitiesMichelle L Krishnan, Elizabeth Berry-Kravis, Jamie K Capal, et al.
European Journal of Paediatric Neurology : EJPN : Official Journal of the European Paediatric Neurology Society|July 15, 2018
Short-term safety of mTOR inhibitors in infants and very young children with tuberous sclerosis complex (TSC): Multicentre clinical experienceDarcy A Krueger, Jamie K Capal, Paolo Curatolo, et al.
BMC Medicine|August 8, 2023
Understanding the impact of tuberous sclerosis complex: development and validation of the TSC-PROMAnnelieke R Müller, Michiel A J Luijten, Lotte Haverman, et al.
BMC Medicine|October 23, 2023
Correction: Understanding the impact of tuberous sclerosis complex: development and validation of the TSC-PROMAnnelieke R Müller, Michiel A J Luijten, Lotte Haverman, et al.
Annals of the Child Neurology Society|December 27, 2024
Preventative treatment of tuberous sclerosis complex with sirolimus: Phase I safety and efficacy resultsJamie K Capal, David M Ritter, David Neal Franz, et al.
Molecular Cancer Research : MCR|July 16, 2017
Tuberin Regulates Prostaglandin Receptor-Mediated Viability, via Rheb, in mTORC1-Hyperactive CellsChenggang Li, Xiaolei Liu, Yang Liu, et al.
Frontiers in Psychiatry|March 17, 2022
Empowering Families Through Technology: A Mobile-Health Project to Reduce the TAND Identification and Treatment Gap (TANDem)Tosca-Marie Heunis, Stacey Bissell, Anna W Byars, et al.
Journal of Neurodevelopmental Disorders|September 14, 2023
International consensus recommendations for the identification and treatment of tuberous sclerosis complex-associated neuropsychiatric disorders (TAND)Petrus J de Vries, Tosca-Marie Heunis, Stephanie Vanclooster, et al.
Pageof 4